Samumed Revenue and Competitors

Location

$778M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Samumed's estimated annual revenue is currently $36.4M per year.(i)
  • Samumed received $440.0M in venture funding in November 2018.
  • 0
  • Samumed's total funding is $778M.
  • Samumed's current valuation is $12B.

Employee Data

    00
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

Samumed is a leader in medical research and development for tissue-level regeneration. With our platform's origins in small molecule-based Wnt pathway modulation, we develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.

keywords:Biotechnology,Customer Support,Education,Healthcare,Human Resources Hr,Pharmaceuticals

$778M

Total Funding

N/A

Number of Employees

$36.4M

Revenue (est)

N/A

Employee Growth %

$12B

Valuation

N/A

Accelerator

Samumed News

2022-04-17 - The health care leaders on Forbes' 'World's Billionaires List ...

Osman Kibar, founder and CEO of biotech firm Samumed, with $2.3 billion. 1397. Phillip Frost, a long-time health care investor and founder,...

2019-08-15 - In conversation with Samumed CEO Osman Kibar: Drugging ...

Founded in 2008, Samumed has spent most of its lifetime working under the radar. It came out of the shadows in 2016 with a war chest of $220 ...

2019-08-15 - In conversation with Samumed CEO Osman Kibar: Drugging Wnt, restoring youth and unconventional capital

Founded in 2008, Samumed has spent most of its lifetime working under the radar. It came out of the shadows in 2016 with a war chest of $220 million drawn from investors including Ikea’s private venture arm and some very wealthy individuals along with a pipeline of drugs it says can reverse agin ...

2019-05-02 - Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical ...

SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has finalized the design of its phase 3 clinical ...

2019-02-28 - Samumed Announces Positive End-of-Phase 2 Meeting with ...

SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has successfully completed an End-of-Phase 2 ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18M0N/A$168.6M
#2
$8.4M0N/AN/A
#3
$11.7M0N/A$4.4M
#4
$1.7M0N/AN/A
#5
$18.3M0N/A$79M

Samumed Funding

DateAmountRoundLead InvestorsReference
2018-08-07$438.0MA-6Article
2018-11-27$440.0MAVickers Venture PartnersArticle